[go: up one dir, main page]

EA199801017A1 - Композиции для лечения заболеваний, опосредованных циклооксигеназой-2, способ лечения воспалительного заболевания - Google Patents

Композиции для лечения заболеваний, опосредованных циклооксигеназой-2, способ лечения воспалительного заболевания

Info

Publication number
EA199801017A1
EA199801017A1 EA199801017A EA199801017A EA199801017A1 EA 199801017 A1 EA199801017 A1 EA 199801017A1 EA 199801017 A EA199801017 A EA 199801017A EA 199801017 A EA199801017 A EA 199801017A EA 199801017 A1 EA199801017 A1 EA 199801017A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cyclooxygenase
diseases
treatment
relates
compound
Prior art date
Application number
EA199801017A
Other languages
English (en)
Other versions
EA001596B1 (ru
Inventor
Бруно Хэнкок
Конрад Винтерс
Барри Гертц
Эллиот Эхрич
Original Assignee
Мерк, Энд Ко., Инк.
Мерк, Фросст Канада, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199801017(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Мерк, Энд Ко., Инк., Мерк, Фросст Канада, Инк. filed Critical Мерк, Энд Ко., Инк.
Publication of EA199801017A1 publication Critical patent/EA199801017A1/ru
Publication of EA001596B1 publication Critical patent/EA001596B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)

Abstract

Изобретение относится к фармацевтической композиции, предназначенной для лечения заболеваний, опосредованных циклооксигеназой-2, приемлемой для одноразового суточного введения, включающей соединение, ингибирующее циклооксигеназу-2, отличающееся высокой способностью ингибирования, долгим полупериодом существования и высокой степенью специфичности предпочтительного ингибирования циклооксигеназы-2, а не циклооксигеназы-1. Такая композиция представлена 3-фенил-4-(4-метилсульфонил)фенил)-2-(5Н)-фураноном. В одном своем аспекте изобретение относится к фармацевтической композиции для лечения циклооксигеназа-2 опосредованных заболеваний, приемлемой для перорального введения один раз в сутки, включающей 5-125 мг вышеуказанного соединения. Изобретение также относится к способу лечения циклооксигеназа-2 опосредованных заболеваний, включающему пероральное введение один раз в сутки 5-125 мг вышеуказанного соединения. Изобретение также относится к применению вышеуказанного соединения для получения лекарственного средства, содержащего 5-125 мг указанного соединения для одноразового суточного введения для лечения заболеваний, опосредованных циклооксигеназой-2.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199801017A 1996-05-17 1997-05-13 Композиции для лечения заболеваний , опосредованных циклооксигеназой-2, способ лечения воспалительного заболевания EA001596B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
PCT/US1997/008041 WO1997044028A1 (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Publications (2)

Publication Number Publication Date
EA199801017A1 true EA199801017A1 (ru) 1999-04-29
EA001596B1 EA001596B1 (ru) 2001-06-25

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199801017A EA001596B1 (ru) 1996-05-17 1997-05-13 Композиции для лечения заболеваний , опосредованных циклооксигеназой-2, способ лечения воспалительного заболевания

Country Status (28)

Country Link
US (1) US6063811A (ru)
EP (1) EP0910368A1 (ru)
JP (1) JPH11512754A (ru)
KR (1) KR100373622B1 (ru)
CN (1) CN1140267C (ru)
AR (1) AR012014A1 (ru)
AU (1) AU3004997A (ru)
BG (1) BG103000A (ru)
BR (1) BR9709097A (ru)
CA (1) CA2254061C (ru)
CO (1) CO5050370A1 (ru)
CZ (1) CZ291463B6 (ru)
DZ (1) DZ2200A1 (ru)
EA (1) EA001596B1 (ru)
EE (1) EE03746B1 (ru)
HR (1) HRP970262A2 (ru)
HU (1) HUP9902889A3 (ru)
ID (1) ID16921A (ru)
IL (1) IL126899A (ru)
IS (1) IS4891A (ru)
MY (1) MY116201A (ru)
NO (1) NO985342L (ru)
NZ (1) NZ332670A (ru)
PE (1) PE66998A1 (ru)
PL (1) PL188649B1 (ru)
SK (1) SK284330B6 (ru)
TR (1) TR199802345T2 (ru)
WO (1) WO1997044028A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045913A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
NZ519466A (en) * 1999-12-22 2004-02-27 Pharmacia Corp Sustained-release formulation of a cyclooxygenase-2 inhibitor
MXPA02012344A (es) 2000-06-13 2004-02-26 Wyeth Corp Composiciones y anti-inflamatorias que contienen inhibidores cox-2.
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
CA2419592A1 (en) * 2000-08-18 2002-02-28 Pharmacia Corporation Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US20040132780A1 (en) * 2001-05-04 2004-07-08 Allen Christopher P. Method and compositions for treating migraines
AR036312A1 (es) * 2001-08-31 2004-08-25 Novartis Ag Composicion farmaceutica
IL160848A0 (en) * 2001-09-26 2004-08-31 Pharmacia Corp Organoleptically acceptable intraorally disintegrating compositions
SK1662004A3 (sk) * 2001-10-10 2005-07-01 Pharmacia Corporation Intraorálne dezintegrujúce prípravky valdecoxidu pripravené rozprašovacím sušením
PE20040288A1 (es) * 2002-03-07 2004-06-24 Novartis Ag Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.
WO2020210341A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with cox-2 selective non-steroidal antiinflammatory drugs
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
JP2788677B2 (ja) * 1994-01-10 1998-08-20 メルク フロスト カナダ インコーポレーテツド Ｃｏｘ−２阻害剤としてのフェニル複素環

Also Published As

Publication number Publication date
CA2254061C (en) 2003-12-02
EP0910368A1 (en) 1999-04-28
CA2254061A1 (en) 1997-11-27
CO5050370A1 (es) 2001-06-27
MY116201A (en) 2003-11-28
ID16921A (id) 1997-11-20
EA001596B1 (ru) 2001-06-25
BG103000A (en) 1999-09-30
NO985342D0 (no) 1998-11-16
CZ373898A3 (cs) 1999-06-16
US6063811A (en) 2000-05-16
HUP9902889A3 (en) 2002-04-29
KR100373622B1 (ko) 2003-07-12
BR9709097A (pt) 1999-08-03
EE9800393A (et) 1999-06-15
SK284330B6 (sk) 2005-01-03
CN1140267C (zh) 2004-03-03
PL329940A1 (en) 1999-04-26
IS4891A (is) 1998-11-10
KR20000011082A (ko) 2000-02-25
HUP9902889A2 (hu) 2002-01-28
HRP970262A2 (en) 1998-06-30
PL188649B1 (pl) 2005-03-31
IL126899A0 (en) 1999-09-22
EE03746B1 (et) 2002-06-17
NO985342L (no) 1998-11-16
NZ332670A (en) 2000-07-28
PE66998A1 (es) 1998-10-24
JPH11512754A (ja) 1999-11-02
CZ291463B6 (cs) 2003-03-12
SK156798A3 (en) 2000-01-18
CN1225010A (zh) 1999-08-04
WO1997044028A1 (en) 1997-11-27
DZ2200A1 (fr) 2004-06-20
IL126899A (en) 2004-03-28
TR199802345T2 (xx) 1999-03-22
HK1021623A1 (en) 2000-06-23
AR012014A1 (es) 2000-09-27
AU3004997A (en) 1997-12-09

Similar Documents

Publication Publication Date Title
EA199801017A1 (ru) Композиции для лечения заболеваний, опосредованных циклооксигеназой-2, способ лечения воспалительного заболевания
DK0828724T3 (da) 5-oxygenerede diaryl-2-(5H)-furanoner som COX-2-inhibitorer
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200000718A1 (ru) Композиции целекоксиба
ATE232856T1 (de) Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
UA41297C2 (ru) Производные индола, фармацевтическая композиция и способ лечения
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
ATE208397T1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
PT948527E (pt) Novos derivados de ciclosporina sua preparacao e composicoes farmaceuticas que os contem
ATE189218T1 (de) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
CA2241904A1 (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
RU94044454A (ru) Ингибитор аутоимунных заболеваний
BG98827A (bg) Фармацевтичен състав и метод за неговото получаване
RU98101105A (ru) Новое применение в медицинских целях
BG103426A (en) Derivatives of substituted 4-biphenyl-4-hydroxy-oil acids as inhibitors of matrix metalloproteases
BG101605A (bg) Ентерокинетични бензамиди
PT100415A (pt) Novas morfolinas de accao farmaceutica, e processo para a sua preparacao
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
FR2744445B1 (fr) Composes biphenyles nouveaux et/ou a titre de medicament, compositions pharmaceutiques les contenant, leur procede de preparation et les intermediaires de ce procede
BR9502072A (pt) Composto metodo para o tratamento de uma condiçao médica e composiçao farmaceutica
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU

PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM